NCT00085124
Clinical Trial Information
Trial Number: NCT00085124 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Trial Title:
A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) ≥ 60 Years
Study ID:
CALGB-10201
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00085124-D2 | This dataset contains adverse event data. NCT00085124-D1 contains patient characteristics and outcome data. |
| NCT00085124-D1 | This dataset contains patient characteristics and outcome data presented in the publication. NCT00085124-D2 contains adverse event information. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®